Methods and kit for early detection of acute coronary syndrome and prediction of adverse cardiac events

Abstract

The invention provides methods for early diagnosis or detection of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject.

1. A method for detecting acute coronary syndrome in a human subject comprising the steps of:
 obtaining a test sample from the biological fluid of the human subject, wherein the biological fluid is selected from a group comprising whole blood, serum and plasma; 
 analyzing the test sample for amount of catalytic iron, wherein the step of analyzing comprises comparing the amount of catalytic iron with a predetermined amount, and wherein the predetermined amount is at least about 0.3 μ mole/L; and 
 detecting acute coronary syndrome in the human subject based on the analysis of the test sample for the amount of catalytic iron. 
 
     
     
       2. The method as claimed in  claim 1 , wherein the test sample is obtained within about six hours after the onset of chest pain in the human subject. 
     
     
       3. A method for detecting acute coronary syndrome in a human subject comprising the steps of:
 obtaining a test sample from the biological fluid of the human subject, wherein the biological fluid is selected from a group comprising whole blood, serum and plasma; 
 analyzing the test sample for amount of bleomycin-detectable iron, wherein the step of analyzing comprises comparing the amount of bleomycin-detectable iron with a predetermined amount, and wherein the predetermined amount is at least about 0.3 μ mole/L; and detecting acute coronary syndrome in the human subject based on the analysis of the test sample for the amount of bleomycin-detectable iron. 
 
     
     
       4. The method as claimed in  claim 3 , wherein the test sample is obtained within about six hours after the onset of chest pain in the human subject. 
     
     
       5. A method for differentiating chest pain corresponding to acute coronary syndrome from non-cardiac chest pain in a human subject comprising the steps of:
 obtaining a test sample from the biological fluid of the human subject, wherein the biological fluid is selected from a group comprising whole blood, serum and plasma; 
 analyzing the test sample for amount of catalytic iron comparing the amount of catalytic iron with a predetermined amount, and wherein the predetermined amount is at least about 0.3 μ mole/L; and 
 differentiating chest pain corresponding to the acute coronary syndrome from the non-cardiac chest pain based on the analysis of the test sample for the amount of catalytic iron. 
 
     
     
       6. A kit for detecting acute coronary syndrome within about six hours of onset of chest pain in a human subject comprising a receptacle means for receiving a test sample from the biological fluid of the human subject, wherein the biological fluid is selected from a group comprising whole blood, serum and plasma, means for analyzing the test sample for amount of catalytic iron, wherein means for analyzing comprises means for comparing the amount of catalytic iron with a predetermined amount, and wherein the predetermined amount is at least about 0.3 μ mole/L, and means for detecting acute coronary syndrome in the human subject based on the analysis of the test sample for the amount of catalytic iron. 
     
     
       7. The method of  claim 1 , wherein the step of analyzing comprises comparing the amount of catalytic iron with that of levels of catalytic iron found in a control population. 
     
     
       8. The method of  claim 3 , wherein the step of analyzing comprises comparing the amount of Bleomycin-detectable iron with that of levels of bleomycin-detectable iron found in a control population. 
     
     
       9. The method of  claim 5 , wherein the step of analyzing comprises comparing the amount of catalytic iron with that of levels of catalytic iron found in a control population.